Galapagos increases share capital through subscription right exercises
20 Juni 2022 - 10:01PM
Galapagos increases share capital through subscription right
exercises
Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated
information – Galapagos NV (Euronext & NASDAQ: GLPG) announces
a share capital increase arising from subscription right
exercises.
Galapagos issued 80,290 new ordinary shares on 20 June 2022, for
a total capital increase (including issuance premium) of EUR
1,459,506.60.
Pursuant to the subscription right exercise program
for Galapagos’ executive committee, the members of the executive
committee automatically are committed to exercise a minimum number
of subscription rights, subject to certain conditions. In
accordance with the rules of this program, one executive committee
member exercised 5,000 subscription rights.
In accordance with Belgian transparency
legislation1, Galapagos also wishes to note that its total share
capital currently amounts to EUR 355,533,029.01, the total number
of securities conferring voting rights amounts to 65,728,511, which
is also the total number of voting rights (the denominator), and
all securities conferring voting rights and all voting rights are
of the same category. The total number of rights (formerly known as
‘warrants’) to subscribe to not yet issued securities conferring
voting rights is (i) 9,060,766 subscription rights under several
outstanding personnel subscription right plans, which equals
9,060,766 voting rights that may result from the exercise of those
subscription rights, and (ii) 1 subscription right issued to Gilead
Therapeutics to subscribe for a maximum number of shares that is
sufficient to bring the shareholding of Gilead (and its affiliated
companies) to 29.9% of the actually issued and outstanding shares
after the exercise of such subscription right. The foregoing
excludes the 2,326,025 subscription rights of Subscription Right
Plan 2022 BE, Subscription Right Plan 2022 RMV and Subscription
Right Plan 2022 ROW, which were created subject to acceptance.
Galapagos does not have any convertible bonds or shares without
voting rights outstanding.
About GalapagosGalapagos NV
discovers, develops, and commercializes small molecule medicines
with novel modes of action. Our pipeline comprises discovery
through Phase 3 programs in inflammation, fibrosis, and other
indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development,
and commercialization of innovative medicines. More information at
www.glpg.com.Contact
Investors:
Sofie Van GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63
ir@glpg.com
Media:
Marieke VermeerschHead of Corporate Communication+32 479 490
603
media@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
1Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market (as amended from time to time).
- Galapagos increases share capital through subscription right
exercises
Galapagos (EU:GLPG)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Galapagos (EU:GLPG)
Historical Stock Chart
Von Apr 2023 bis Apr 2024